Fibroma - 96 Studies Found Completed : Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 : Plexiform Neurofibromas NF1 : 2000-11-03 Recruiting : PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) : Neurofibroma, Plexiform Precursor Cell Lymphoblastic Leukemia-L : 2015-03-17 : Drug: PLX3397 Take oral drug daily for a 28 day cycle Terminated : Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma : Neurofibromatosis Type 1 Precancerous Condition : 2003-05-06 : Radiation: fludeoxyglucose F 18 Radiation: Completed : Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas : Neurofibromatosis Type 1 Precancerous Condition : 2003-02-05 : Drug: pirfenidone Completed : Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas : Neurofibromatosis Type 1 Precancerous Condition : 2002-02-14 : Drug: Methotrexate Methotrexat Completed : Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development : Cancer : 2006-06-19 Recruiting : Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations : Cancer : 2014-04-24 : Drug: Trametinib Trametinib is Completed : PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma : Neoplasm of Uncertain Malignant Potential Unspecified Childhood Solid Tumor, Protocol Specif : 2005-11-11 : Biological: PEG-interferon alfa-2a Recruiting : AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors : Neurofibromatosis 1 Neurofibromatosis Type 1 NF 1 : 2011-05-27 : Drug: AZD6244 AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until una Completed : Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas : Neurofibromatosis : 2012-08-22 : Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects <<< Previous | Next >>>
